Literature DB >> 10472115

The pathophysiology of developmental and acute laminitis.

D M Hood1.   

Abstract

This review implies that although we know more regarding the enigma of developmental and acute laminitis today than previously, there is still more to investigate. As these investigations are conducted and interpreted, new and more effective preventive and therapeutic regimens are likely to be developed, tested, and made available. As this occurs, the impact of laminitis should undoubtedly decrease. Unfortunately, due to the lack of clinical symptoms in the developmental phase and the shortness of the acute phase, it is also evident that the two sequelae of acute laminitis, subacute and chronic laminitis, are likely to continue to pose a major problem for some time.

Entities:  

Mesh:

Year:  1999        PMID: 10472115     DOI: 10.1016/s0749-0739(17)30148-7

Source DB:  PubMed          Journal:  Vet Clin North Am Equine Pract        ISSN: 0749-0739            Impact factor:   1.792


  4 in total

1.  Cytokeratins of the stratum medium and stratum internum of the equine hoof wall in acute laminitis.

Authors:  O Wattle
Journal:  Acta Vet Scand       Date:  2000       Impact factor: 1.695

2.  Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis.

Authors:  Alonso G P Guedes; Christophe Morisseau; Albert Sole; Joao H N Soares; Arzu Ulu; Hua Dong; Bruce D Hammock
Journal:  Vet Anaesth Analg       Date:  2013-03-07       Impact factor: 1.648

Review 3.  Ten years of the horse reference genome: insights into equine biology, domestication and population dynamics in the post-genome era.

Authors:  T Raudsepp; C J Finno; R R Bellone; J L Petersen
Journal:  Anim Genet       Date:  2019-09-30       Impact factor: 3.169

4.  Effect of short-term hyperinsulinemia on the localization and expression of endothelin receptors A and B in lamellar tissue of the forelimbs of horses.

Authors:  Felicia C Gauff; Bianca Patan-Zugaj; Theresia F Licka
Journal:  Am J Vet Res       Date:  2014-04       Impact factor: 1.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.